Trial
NCT01133756
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Eisai Inc.
Collaborators
PharmaBio Development Inc.
Condition
Ovarian Cancer
Intervention
Lenvatinib
Why stopped
poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-22